In a retrospective study of 122 patients with HER2-mutant lung cancer, programmed cell death-ligand 1 (PD-L1) expression was lower but tumor mutation burden (TMB) was similar to those in unselected lung cancers.81 This evidence concerns the gene ERBB2 and lung cancer.